{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:41Z","timestamp":1790474141944,"version":"4.1.0"},"reference-count":146,"publisher":"European Respiratory Society (ERS)","issue":"147","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2018,1,13]]},"published-print":{"date-parts":[[2018,3,31]]},"abstract":"<jats:p>Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have been approved in this disease. However, its incidence is expected to increase significantly, particularly in developing countries. Consequently, drug repurposing appears as an attractive strategy for drug development in MPM, since the known pharmacology and safety profile based on previous approvals of repurposed drugs allows for faster time-to-market for patients and lower treatment cost. This is critical in low- and middle-income countries where access to expensive drugs is limited. This review assesses the published preclinical and clinical data about drug repurposing in MPM.<\/jats:p><jats:p>In this review, we identified 11 therapeutic classes that could be repositioned in mesothelioma. Most of these treatments have been evaluated<jats:italic>in vitro<\/jats:italic>, half have been evaluated<jats:italic>in vivo<\/jats:italic>in animal models of MPM and only three (<jats:italic>i.e.<\/jats:italic>valproate, thalidomide and zoledronic acid) have been investigated in clinical trials, with limited benefits so far. Efforts could be coordinated to pursue further investigations and test promising drugs identified in preclinical experiments in appropriately designed clinical trials.<\/jats:p>","DOI":"10.1183\/16000617.0098-2017","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T11:20:17Z","timestamp":1521026417000},"page":"170098","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?"],"prefix":"10.1183","volume":"27","author":[{"given":"Arnaud","family":"Boyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Mascaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,3,14]]},"reference":[{"key":"2024102403324009000_27.147.170098.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1468"},{"key":"2024102403324009000_27.147.170098.2","doi-asserted-by":"crossref","unstructured":"Pantziarka P , Hutchinson L , Andr\u00e9 N , et al. Next generation metronomic chemotherapy\u2014report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, May 6\u20138, 2016, Mumbai. Ecancermedicalscience 2016; 10.","DOI":"10.3332\/ecancer.2016.689"},{"key":"2024102403324009000_27.147.170098.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70056-1"},{"key":"2024102403324009000_27.147.170098.4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1188\/16.ONF.118-120","article-title":"Global cancer disparities and the need for new initiatives","volume":"43","author":"LeBaron","year":"2016","journal-title":"Oncol Nurs Forum"},{"key":"2024102403324009000_27.147.170098.5","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.9224"},{"key":"2024102403324009000_27.147.170098.6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.343"},{"key":"2024102403324009000_27.147.170098.7","doi-asserted-by":"publisher","DOI":"10.2174\/138945011795677764"},{"key":"2024102403324009000_27.147.170098.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.02.027"},{"key":"2024102403324009000_27.147.170098.9","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"2024102403324009000_27.147.170098.10","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09091932"},{"key":"2024102403324009000_27.147.170098.11","first-page":"162","article-title":"Latency periods in asbestos-related mesothelioma of the pleura","volume":"6","author":"Bianchi","year":"1997","journal-title":"Eur J Cancer Prev"},{"key":"2024102403324009000_27.147.170098.12","unstructured":"World Health Organization . Asbestos: Elimination of Asbestos-Related Diseases. 2006. www.who.int\/mediacentre\/factsheets\/fs343\/en\/ Date last updated: August 2017."},{"key":"2024102403324009000_27.147.170098.13","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.20209"},{"key":"2024102403324009000_27.147.170098.14","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.086678"},{"key":"2024102403324009000_27.147.170098.15","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-200006000-00006"},{"key":"2024102403324009000_27.147.170098.16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5491\/SHAW.2010.1.2.103","article-title":"Towards elimination of asbestos-related diseases: a theoretical basis for international cooperation","volume":"1","author":"Takahashi","year":"2010","journal-title":"Saf Health Work"},{"key":"2024102403324009000_27.147.170098.17","doi-asserted-by":"crossref","unstructured":"Virta RL . Worldwide Asbestos Supply and Consumption Trends from 1900 through 2003. US Department of the Interior, US Geological Survey. 2006. https:\/\/pubs.usgs.gov\/circ\/2006\/1298\/c1298.pdf","DOI":"10.3133\/cir1298"},{"key":"2024102403324009000_27.147.170098.18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031811-124704"},{"key":"2024102403324009000_27.147.170098.19","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.20198"},{"key":"2024102403324009000_27.147.170098.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2024102403324009000_27.147.170098.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2024102403324009000_27.147.170098.22","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(15)01311-2","article-title":"A new standard for malignant pleural mesothelioma","volume":"387","author":"Zauderer","year":"2016","journal-title":"Lancet"},{"key":"2024102403324009000_27.147.170098.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70056-2"},{"key":"2024102403324009000_27.147.170098.24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JTO.0b013e31802f3813","article-title":"Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment","volume":"2","author":"S\u00f8rensen","year":"2007","journal-title":"J Thorac Oncol"},{"key":"2024102403324009000_27.147.170098.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.04.001"},{"key":"2024102403324009000_27.147.170098.26","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S"},{"key":"2024102403324009000_27.147.170098.27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024102403324009000_27.147.170098.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0804"},{"key":"2024102403324009000_27.147.170098.29","doi-asserted-by":"publisher","DOI":"10.1002\/bdrc.21096"},{"key":"2024102403324009000_27.147.170098.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80085-1"},{"key":"2024102403324009000_27.147.170098.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.4082"},{"key":"2024102403324009000_27.147.170098.32","first-page":"5767","article-title":"Therapeutic potential of thalidomide and its analogues in the treatment of cancer","volume":"35","author":"Sherbet","year":"2015","journal-title":"Anticancer Res"},{"key":"2024102403324009000_27.147.170098.33","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00262-014-1571-6","article-title":"Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation","volume":"63","author":"De Keersmaecker","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2024102403324009000_27.147.170098.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"2024102403324009000_27.147.170098.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61537-2"},{"key":"2024102403324009000_27.147.170098.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.10.005"},{"key":"2024102403324009000_27.147.170098.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70125-6"},{"key":"2024102403324009000_27.147.170098.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9116"},{"key":"2024102403324009000_27.147.170098.39","doi-asserted-by":"publisher","DOI":"10.1038\/nrd772"},{"key":"2024102403324009000_27.147.170098.40","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00037310"},{"key":"2024102403324009000_27.147.170098.41","doi-asserted-by":"publisher","DOI":"10.1006\/cbir.2002.0925"},{"key":"2024102403324009000_27.147.170098.42","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.V93.4.1308","article-title":"Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach","volume":"93","author":"Dimitroulakos","year":"1999","journal-title":"Blood"},{"key":"2024102403324009000_27.147.170098.43","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10440"},{"key":"2024102403324009000_27.147.170098.44","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000012283.15789.67"},{"key":"2024102403324009000_27.147.170098.45","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/22.8.1139"},{"key":"2024102403324009000_27.147.170098.46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11010-010-0553-z","article-title":"Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP","volume":"345","author":"Arnold","year":"2010","journal-title":"Mol Cell Biochem"},{"key":"2024102403324009000_27.147.170098.47","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21832"},{"key":"2024102403324009000_27.147.170098.48","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.ejca.2014.08.005","article-title":"Simvastatin plus capecitabine\u2013cisplatin versus placebo plus capecitabine\u2013cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study","volume":"50","author":"Kim","year":"2014","journal-title":"Eur J Cancer"},{"key":"2024102403324009000_27.147.170098.49","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/bjc.2015.371","article-title":"A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI\/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer","volume":"113","author":"Lim","year":"2015","journal-title":"Br J Cancer"},{"key":"2024102403324009000_27.147.170098.50","unstructured":"NCT00433498 . Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy with or Without Pravastatin in Treating Patients With Small Cell Lung Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00433498 Date last updated: December 3, 2014."},{"key":"2024102403324009000_27.147.170098.51","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3892\/ijo.2014.2584","article-title":"Enhanced apoptosis by pemetrexed and simvastatin in malignant mesothelioma and lung cancer cells by reactive oxygen species-dependent mitochondrial dysfunction and Bim induction","volume":"45","author":"Hwang","year":"2014","journal-title":"Int J Oncol"},{"key":"2024102403324009000_27.147.170098.52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.canlet.2013.07.015","article-title":"Synergistic effect of combined treatment with gamma-tocotrienol and statin on human malignant mesothelioma cells","volume":"339","author":"Tuerdi","year":"2013","journal-title":"Cancer Lett"},{"key":"2024102403324009000_27.147.170098.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2011.06.037"},{"key":"2024102403324009000_27.147.170098.54","doi-asserted-by":"publisher","DOI":"10.1021\/cb600362d"},{"key":"2024102403324009000_27.147.170098.55","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31828c3950"},{"key":"2024102403324009000_27.147.170098.56","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-314"},{"key":"2024102403324009000_27.147.170098.57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9525"},{"key":"2024102403324009000_27.147.170098.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2013.08.035"},{"key":"2024102403324009000_27.147.170098.59","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.2.124"},{"key":"2024102403324009000_27.147.170098.60","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29852"},{"key":"2024102403324009000_27.147.170098.61","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22397"},{"key":"2024102403324009000_27.147.170098.62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/ijo.2014.2716","article-title":"Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma","volume":"46","author":"Lam","year":"2015","journal-title":"Int J Oncol"},{"key":"2024102403324009000_27.147.170098.63","first-page":"447","article-title":"Treatment of alcohol dependence: recent progress and reduction of consumption","volume":"105","author":"Testino","year":"2014","journal-title":"Minerva Med"},{"key":"2024102403324009000_27.147.170098.64","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0424"},{"key":"2024102403324009000_27.147.170098.65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093711"},{"key":"2024102403324009000_27.147.170098.66","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.1.272"},{"key":"2024102403324009000_27.147.170098.67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-1086"},{"key":"2024102403324009000_27.147.170098.68","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh322"},{"key":"2024102403324009000_27.147.170098.69","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-1945"},{"key":"2024102403324009000_27.147.170098.70","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.196"},{"key":"2024102403324009000_27.147.170098.71","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou155"},{"key":"2024102403324009000_27.147.170098.72","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-214"},{"key":"2024102403324009000_27.147.170098.73","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-464"},{"key":"2024102403324009000_27.147.170098.74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2010.03.014"},{"key":"2024102403324009000_27.147.170098.75","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.6.7933"},{"key":"2024102403324009000_27.147.170098.76","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1871520611313020018","article-title":"Metformin: a rising star to fight the epithelial mesenchymal transition in oncology","volume":"13","author":"Barri\u00e8re","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"2024102403324009000_27.147.170098.77","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00027-3"},{"key":"2024102403324009000_27.147.170098.78","unstructured":"NCT01101438 . A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01101438 Date last updated: March 24, 2017."},{"key":"2024102403324009000_27.147.170098.79","unstructured":"NCT02065687 . Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients with Stage III, IV, or Recurrent Endometrial Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02065687 Date last updated: August 23, 2017."},{"key":"2024102403324009000_27.147.170098.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2005.06.001"},{"key":"2024102403324009000_27.147.170098.81","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.drudis.2017.08.001","article-title":"Tocotrienols: the unsaturated sidekick shifting new paradigms in vitamin E therapeutics","volume":"22","author":"Kanchi","year":"2017","journal-title":"Drug Discov Today"},{"key":"2024102403324009000_27.147.170098.82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.arr.2014.01.001","article-title":"Vitamin E\u2013gene interactions in aging and inflammatory age-related diseases: implications for treatment. A systematic review","volume":"14","author":"Mocchegiani","year":"2014","journal-title":"Ageing Res Rev"},{"key":"2024102403324009000_27.147.170098.83","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.18632\/oncotarget.1876","article-title":"\u03b3-Tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT\/mTOR pathway in an orthotopic mouse model","volume":"5","author":"Siveen","year":"2014","journal-title":"Oncotarget"},{"key":"2024102403324009000_27.147.170098.84","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/153537020523000402","article-title":"\u03b3-Tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor \u03baB activity","volume":"230","author":"Shah","year":"2005","journal-title":"Exp Biol Med"},{"key":"2024102403324009000_27.147.170098.85","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.3107"},{"key":"2024102403324009000_27.147.170098.86","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2726"},{"key":"2024102403324009000_27.147.170098.87","unstructured":"NCT02560337 . Cabazitaxel vs. Tocotrienol in Patients with Recurrent Ovarian Cancer After Failure of Standard Therapy (CaTo-ROC). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02560337 Date last updated: November 17, 2017."},{"key":"2024102403324009000_27.147.170098.88","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2009.02.007"},{"key":"2024102403324009000_27.147.170098.89","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4161\/cbt.22953","article-title":"Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis","volume":"14","author":"Slipicevic","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"2024102403324009000_27.147.170098.90","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0278"},{"key":"2024102403324009000_27.147.170098.91","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1998.13.4.581"},{"key":"2024102403324009000_27.147.170098.92","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033453640"},{"key":"2024102403324009000_27.147.170098.93","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11128"},{"key":"2024102403324009000_27.147.170098.94","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.18632\/oncotarget.2731","article-title":"Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma","volume":"6","author":"Salaroglio","year":"2015","journal-title":"Oncotarget"},{"key":"2024102403324009000_27.147.170098.95","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"2024102403324009000_27.147.170098.96","first-page":"39","article-title":"A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma","volume":"12","author":"Jamil","year":"2017","journal-title":"Lung Cancer"},{"key":"2024102403324009000_27.147.170098.97","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-10-1247"},{"key":"2024102403324009000_27.147.170098.98","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.24.6969"},{"key":"2024102403324009000_27.147.170098.99","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.853037"},{"key":"2024102403324009000_27.147.170098.100","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20774"},{"key":"2024102403324009000_27.147.170098.101","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/0019-509X.118741","article-title":"Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02","volume":"50","author":"Traore","year":"2013","journal-title":"Indian J Cancer"},{"key":"2024102403324009000_27.147.170098.102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.04.038"},{"key":"2024102403324009000_27.147.170098.103","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9700-3"},{"key":"2024102403324009000_27.147.170098.104","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29085"},{"key":"2024102403324009000_27.147.170098.105","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1579"},{"key":"2024102403324009000_27.147.170098.106","doi-asserted-by":"publisher","DOI":"10.1038\/343425a0"},{"key":"2024102403324009000_27.147.170098.107","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.04.011"},{"key":"2024102403324009000_27.147.170098.108","doi-asserted-by":"crossref","first-page":"e0144797","DOI":"10.1371\/journal.pone.0144797","article-title":"From bench to bedside: attempt to evaluate repositioning of drugs in the treatment of metastatic small cell lung cancer (SCLC)","volume":"11","author":"Lohinai","year":"2016","journal-title":"PLoS One"},{"key":"2024102403324009000_27.147.170098.109","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1164\/ajrccm.157.5.9709020","article-title":"Lovastatin induces apoptosis in malignant mesothelioma cells","volume":"157","author":"Rubins","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403324009000_27.147.170098.110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2011.05.149","article-title":"Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells","volume":"410","author":"Yamauchi","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"2024102403324009000_27.147.170098.111","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.278754"},{"key":"2024102403324009000_27.147.170098.112","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0599"},{"key":"2024102403324009000_27.147.170098.113","first-page":"507","article-title":"A biography of arsenic and medicine in Hong Kong and China","volume":"17","author":"Au","year":"2011","journal-title":"Hong Kong Med J"},{"key":"2024102403324009000_27.147.170098.114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135795"},{"key":"2024102403324009000_27.147.170098.115","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/cncr.29456","article-title":"Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma","volume":"121","author":"Wang","year":"2015","journal-title":"Cancer"},{"key":"2024102403324009000_27.147.170098.116","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4827(03)00391-4"},{"key":"2024102403324009000_27.147.170098.117","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/srep03105","article-title":"Requirement for phosphorylation of P53 at Ser312 in suppression of chemical carcinogenesis","volume":"3","author":"Slee","year":"2013","journal-title":"Sci Rep"},{"key":"2024102403324009000_27.147.170098.118","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(03)00287-9"},{"key":"2024102403324009000_27.147.170098.119","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21247"},{"key":"2024102403324009000_27.147.170098.120","first-page":"6658","article-title":"Potentiation of nitrogen mustard cytotoxicity by disulfiram, diethyldithiocarbamic acid, and diethylamine in mice","volume":"49","author":"Valeriote","year":"1989","journal-title":"Cancer Res"},{"key":"2024102403324009000_27.147.170098.121","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10972"},{"key":"2024102403324009000_27.147.170098.122","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.113324"},{"key":"2024102403324009000_27.147.170098.123","doi-asserted-by":"crossref","first-page":"e1786","DOI":"10.1038\/cddis.2015.153","article-title":"Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis"},{"key":"2024102403324009000_27.147.170098.124","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2011.10.016"},{"key":"2024102403324009000_27.147.170098.125","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1360"},{"key":"2024102403324009000_27.147.170098.126","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1112"},{"key":"2024102403324009000_27.147.170098.127","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308260"},{"key":"2024102403324009000_27.147.170098.128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006293422603"},{"key":"2024102403324009000_27.147.170098.129","doi-asserted-by":"crossref","first-page":"39342","DOI":"10.18632\/oncotarget.5745","article-title":"Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1","volume":"6","author":"Schellhorn","year":"2015","journal-title":"Oncotarget"},{"key":"2024102403324009000_27.147.170098.130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bcp.12757","article-title":"Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer?","volume":"81","author":"Hou","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2024102403324009000_27.147.170098.131","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2994"},{"key":"2024102403324009000_27.147.170098.132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033093"},{"key":"2024102403324009000_27.147.170098.133","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2016.07.020","article-title":"Metformin and survival of people with type 2 diabetes and pleural mesothelioma: a population-based retrospective cohort study","volume":"99","author":"Wu","year":"2016","journal-title":"Lung Cancer"},{"key":"2024102403324009000_27.147.170098.134","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2007.03.001"},{"key":"2024102403324009000_27.147.170098.135","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.03.063"},{"key":"2024102403324009000_27.147.170098.136","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6882-14-469","article-title":"Cytotoxicity and apoptotic activities of alpha-, gamma-and delta-tocotrienol isomers on human cancer cells","volume":"14","author":"Lim","year":"2014","journal-title":"BMC Complement Altern Med"},{"key":"2024102403324009000_27.147.170098.137","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0052"},{"key":"2024102403324009000_27.147.170098.138","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3892\/or.2012.2010","article-title":"Yes is a central mediator of cell growth in malignant mesothelioma cells","volume":"28","author":"Sato","year":"2012","journal-title":"Oncol Rep"},{"key":"2024102403324009000_27.147.170098.139","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1016\/S0021-9258(18)95953-3","article-title":"Inhibitors of protein biosynthesis. II. Mode of action of anisomycin","volume":"242","author":"Grollman","year":"1967","journal-title":"J Biol Chem"},{"key":"2024102403324009000_27.147.170098.140","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024102403324009000_27.147.170098.141","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24470"},{"key":"2024102403324009000_27.147.170098.142","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","article-title":"Metastatic prostate cancer and the bone: significance and therapeutic options","volume":"68","author":"Gartrel","year":"2015","journal-title":"Eur Urol"},{"key":"2024102403324009000_27.147.170098.143","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/imj.13502","article-title":"Bisphosphonate guidelines for treatment and prevention of myeloma bone disease","volume":"47","author":"Lee","year":"2017","journal-title":"Intern Med J"},{"key":"2024102403324009000_27.147.170098.144","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JTO.0b013e31824c7d43","article-title":"Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners","volume":"7","author":"Okamoto","year":"2012","journal-title":"J Thorac Oncology"},{"key":"2024102403324009000_27.147.170098.145","doi-asserted-by":"crossref","unstructured":"Wakchoure S , Merrell MA , Aldrich W , et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo . Clin Cancer Res 2006: 2862\u20132868.","DOI":"10.1158\/1078-0432.CCR-05-2766"},{"key":"2024102403324009000_27.147.170098.146","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.07.011"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0098-2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T04:59:46Z","timestamp":1740373186000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0098-2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,14]]},"references-count":146,"journal-issue":{"issue":"147","published-online":{"date-parts":[[2018,3,14]]},"published-print":{"date-parts":[[2018,3,31]]}},"alternative-id":["10.1183\/16000617.0098-2017"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0098-2017","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,14]]}}}